Company news
Lexicon Pharmaceuticals, Inc. news in 2019
Lexicon Pharmaceuticals, Inc.'s news releases, calls and decks from 2019, newest first.
Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 Diabetes
December 19, 2019
Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211
December 4, 2019
Lexicon Pharmaceuticals Completes Safety Review of Initial Safety Run-in Cohort of TELE-ABC Study, a Phase 2 Clinical Study of Telotristat Ethyl in Biliary Tract Cancer
December 2, 2019
Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA’s Office of New Drugs for Sotagliflozin in Type 1 Diabetes
December 1, 2019
Lexicon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides a Business Update
November 6, 2019
Lexicon Pharmaceuticals Announces Poster Presentations at the NANETS Annual Multidisciplinary NET Medical Symposium
October 1, 2019
Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement With Sanofi
September 9, 2019